Background We conducted a phase 3, randomized, double-blind, placebo-controlled trial of
sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, in patients …

Epigenetic proteins are intently pursued targets in ligand discovery. So far, successful efforts
have been limited to chromatin modifying enzymes, or so-called epigenetic ‘writers’ and ‘…

Since the molecular revolution of the 1980s, knowledge of the aetiology of cancer has
increased considerably, which has led to the discovery and development of targeted therapies …

… Abou-Alfa, Lawrence Schwartz, Sergio Ricci, Dino Amadori, Armando Santoro, Arie Figer,
Jacques De Greve, Jean-Yves Douillard, Chetan Lathia, Brian Schwartz, Ian Taylor, Marius …

… Abbruzzese, Chenghua Xia, Ronit Simantov, Brian Schwartz, and Peter J. O’Dwyer …
Brian Schwartz … Abbruzzese, Brian Schwartz Provision of study materials or patients …

Context.—Tension-type headache is a highly prevalent condition. Because few population-based
studies have been performed, little is known about its epidemiology.Objectives.—To …

We completed a systematic search of the epidemiologic literature on built environment and
obesity and identified 63 relevant papers, which were then evaluated for the quality of …

Background Lidocaine has been the initial antiarrhythmic drug treatment recommended for
patients with ventricular fibrillation that is resistant to conversion by defibrillator shocks. We …

Purpose BAY 43-9006 is a novel dual-action Raf kinase and vascular endothelial growth
factor receptor inhibitor that inhibits tumor cell proliferation and angiogenesis. This study …

During human CMV infection, there is a preferential expansion of natural killer (NK) cells
expressing the activating CD94–NKG2C receptor complex, implicating this receptor in the …